Find Clinical Trials

All CategoriesMedical Conditions»Urinary/Reproductive Disease»Penile Cancer



Join Paid Clinical Trials



  • Condition:   Penile Cancer
    Interventions:   Drug: Arm A: Atezolizumab and Radiotherapy;   Drug: Arm B: Atezolizumab
    Sponsors:   The Netherlands Cancer Institute;   Hoffmann-La Roche
    Recruiting

  • Conditions:   Penile Cancer;   Squamous Carcinoma
    Intervention:   Drug: Chemotherapy TIP
    Sponsors:   UNICANCER;   National Cancer Institute, France
    Recruiting

  • Conditions:   Penile Cancer;   Advanced Cancer;   Metastatic Cancer
    Interventions:   Drug: Avelumab;   Other: Best Supportive Care
    Sponsor:   University Health Network, Toronto
    Recruiting

  • Conditions:   Penile Cancer;   Penile Neoplasms;   Penile Squamous Cell Carcinoma
    Intervention:   Drug: Avelumab
    Sponsors:   Centre Hospitalier Universitaire de Besancon;   Pfizer
    Not yet recruiting

  • Condition:   Squamous Cell Carcinoma of the Penis, Usual Type
    Interventions:   Procedure: ILND - Inguinal Lymph Node Dissection;   Drug: Paclitaxel;   Drug: Ifosfamide;   Drug: Cisplatin;   Radiation: Intensity modulated radiation treatment (IMRT);   Procedure: Prophylactic PLND - pelvic lymph node dissection
    Sponsors:   Institute of Cancer Research, United Kingdom;   ECOG-ACRIN Cancer Research Group;   Canadian Cancer Trials Group
    Recruiting

  • Conditions:   Cervical Cancer;   Anal Cancer;   Penile Cancer
    Intervention:   Behavioral: Framed HPV vaccination messages
    Sponsor:   University of Maryland
    Not yet recruiting

  • Conditions:   Carcinoma, Squamous Cell;   Head and Neck Neoplasm;   Cervical Neoplasm;   Penile Neoplasms Malignant
    Intervention:   Drug: HPV vaccine
    Sponsors:   University of Southampton;   Biontech AG
    Recruiting

  • Conditions:   Human Papilloma Virus;   Cervical Cancer;   Oropharyngeal Cancer;   Anal Cancer;   Vaginal or Penile Cancer
    Intervention:   Drug: M7824
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Bladder Small Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Kidney Medullary Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Penile Carcinoma;   Metastatic Renal Cell Carcinoma;   Renal Pelvis Urothelial Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Squamous Cell Carcinoma of the Penis;   Stage III Bladder Adenocarcinoma AJCC v6 and v7;   Stage III Bladder Squamous Cell Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Penile Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7;   Stage III Renal Pelvis Cancer AJCC v7;   Stage III Ureter Cancer AJCC v7;   Stage III Urethral Cancer AJCC v7;   Stage IIIa Penile Cancer AJCC v7;   Stage IIIb Penile Cancer AJCC v7;   Stage IV Bladder Adenocarcinoma AJCC v7;   Stage IV Bladder Squamous Cell Carcinoma AJCC v7;   Stage IV Bladder Urothelial Carcinoma AJCC v7;   Stage IV Penile Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Stage IV Renal Pelvis Cancer AJCC v7;   Stage IV Ureter Cancer AJCC v7;   Stage IV Urethral Cancer AJCC v7;   Ureter Urothelial Carcinoma;   Urethral Urothelial Carcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Human Papillomavirus-16 Positive;   Human Papillomavirus-18 Positive;   Metastatic Malignant Neoplasm;   Recurrent Anal Canal Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Malignant Neoplasm;   Recurrent Penile Carcinoma;   Recurrent Vaginal Carcinoma;   Recurrent Vulvar Carcinoma;   Refractory Malignant Neoplasm;   Stage IV Anal Cancer AJCC v8;   Stage IV Cervical Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Vaginal Cancer AJCC v8;   Stage IV Vulvar Cancer AJCC v8;   Stage IVA Cervical Cancer AJCC v8;   Stage IVA Vaginal Cancer AJCC v8;   Stage IVA Vulvar Cancer AJCC v8;   Stage IVB Cervical Cancer AJCC v8;   Stage IVB Vaginal Cancer AJCC v8;   Stage IVB Vulvar Cancer AJCC v8
    Interventions:   Biological: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457;   Biological: Durvalumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Neuroendocrine Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Cell Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Plasmacytoid Urothelial Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Metastatic Sarcomatoid Urothelial Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Carcinoma of Unknown Primary Origin;   Kidney Medullary Carcinoma;   Malignant Germ Cell Tumor;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Malignant Solid Neoplasm;   Metastatic Paraganglioma;   Metastatic Penile Carcinoma;   Paraganglioma;   Skin Squamous Cell Carcinoma;   Small Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma AJCC v7;   Stage IV Penile Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Unresectable Solid Neoplasm;   Vascular Neoplasm
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Genitourinary Cancer;   Adrenocortical Carcinoma;   Non-urothelial Bladder;   Non-urothelial Upper Tract;   Penile Cancer;   Non-adenocarcinoma Prostate Cancer;   Refractory Germ-cell
    Interventions:   Drug: Ipilimumab;   Drug: Nivolumab
    Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer;   Colon Cancer;   Rectal Cancer;   GIST;   Anal Cancer;   Bile Duct Cancer;   Duodenal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Liver Cancer;   Small Intestine Cancer;   Peritoneal Surface Malignancies;   Familial Adenomatous Polyposis;   Lynch Syndrome;   Bladder Cancer;   Kidney Cancer;   Penile Cancer;   Prostate Cancer;   Testicular Cancer;   Ureter Cancer;   Urethral Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer;   Lip Cancer;   Oral Cavity Cancer;   Nasopharyngeal Cancer;   Oropharyngeal Cancer;   Paranasal Sinus Cancer;   Nasal Cavity Cancer;   Salivary Gland Cancer;   Skin Cancer;   CNS Tumor;   CNS Cancer;   Mesothelioma;   Breastcancer;   Leukemia;   Melanoma;   Sarcoma;   Unknown Primary Tumor;   Multiple Myeloma;   Ovarian Cancer;   Endometrial Cancer;   Vaginal Cancer
    Intervention:  
    Sponsor:   University of Nebraska
    Recruiting

  • Conditions:   Human Papillomavirus-Related Carcinoma;   Human Papillomavirus Positive Oropharyngeal Carcinoma;   Human Papillomavirus Positive Cervical Carcinoma;   Human Papillomavirus Positive Anal Carcinoma;   Human Papillomavirus Positive Vulvar Carcinoma;   Human Papillomavirus Positive Penile Carcinoma
    Interventions:   Genetic: HPV Specific T Cells;   Drug: Cytoxan;   Drug: Fludarabine;   Biological: Nivolumab
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   The Methodist Hospital System
    Recruiting

  • Condition:   Penile Squamous Cell Carcinoma
    Intervention:   Drug: Pembrolizumab
    Sponsors:   University of Alabama at Birmingham;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cancer That is Associated With a Chronic Viral Infection;   p16 Positive SCCHN;   Squamous Cell Carcinoma of the Cervix;   p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva;   p16 Positive Squamous Cell Carcinoma of the Penis;   p16 Positive Squamous Cell Carcinoma of the Anus or Anal Canal;   EBER Positive NPC;   EBER Positive Hodgkins and Non-hodgkins Lymphona
    Interventions:   Drug: Valproic Acid;   Biological: Avelumab
    Sponsors:   AHS Cancer Control Alberta;   EMD Serono
    Recruiting

  • Conditions:   Gastrointestinal Stromal Tumors;   Aggressive Systemic Mastocytosis;   Advanced Cancers
    Intervention:   Drug: DCC-2618
    Sponsor:   Deciphera Pharmaceuticals LLC
    Recruiting

  • Conditions:   Prostate Cancer;   Penile Diseases
    Intervention:   Device: RestoreX
    Sponsor:   Mayo Clinic
    Recruiting

  • Condition:   Malignant Neoplasms of Male Genital Organs
    Interventions:   Procedure: Caudal Nerve Block (CNB);   Drug: Ropivacaine;   Drug: Epinephrine;   Drug: Decadron;   Drug: Clonidine;   Drug: Propofol;   Behavioral: Phone Call
    Sponsors:   M.D. Anderson Cancer Center;   Merck Sharp & Dohme Corp.
    Recruiting

Login to Get Started